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Abstract
Background: Angiopoietin-like protein 4 (ANGPTL4) is a metabolic factor that increases plasma triglyceride levels
by inhibiting lipoprotein lipase (LPL). The objective of this study was to investigate the association of ANGPTL4
variants (E40K and T266M) with triglyceride levels and with cardiovascular risk factors, such as metabolic syndrome
(MetS) and obesity in type 2 diabetic Tunisian population.
Methods: We investigated the effect of the tagging single nucleotide polymorphisms (SNPs) rs1044250 (T266M)
and rs116843064 (E40K) with triglyceride (TG) levels and CAD risk factors in a cohort of 220 patients undergoing
coronary angiography for the evaluation of stable CAD, all of whom had (type 2 diabetes) T2D and were at least
overweight. Multivariate logistic regressions were performed on association studies.
Results: TT genotype of rs1044250 (T266M variant) showed a protective effect on CVD risk in CAD group patients
(OR 1.92, 95 % CI 0.601.42, p =0.05) compared with control Group patients (OR 1.17, 95 % CI 0.70–1.66, p = 0.72).
Likewise, GA genotype of rs116843064 (E40K variant): (OR 0.74, 95 % CI 0.54–1.65, p =0.01) for the CAD group
compared with control Group patients (OR 1.12, 95 % CI 0.68–1.74, p = 0.074).
Conclusions: ANGPTL4 variants are associated with, not only lower fasting triglyceride levels, but also a decreased
cardiovascular risk in T2D Tunisian patients. So, T266M and E40K polymorphism predicts cardiovascular disease risk
in Type 2 diabetic Tunisian population
Keywords: Angiopoietin-like protein 4, CVD risk factors, Coronary artery disease, Metabolic syndrome, Obesity, TG
levels
Background
The angiopoietin-like protein 4 (ANGPTL4) peptide, is a
well established regulator of LPL activity and triglyceride
levels. In vitro studies confirm that Angptl4, acting as an
oligomer, inhibits enzymatic hydrolysis of triglycerides
by preventing LPL dimerization [1]. ANGPTL4 has two
common coding single nucleotid polymorphisms (cSNPs):
E40K and T266M. The E40K substitution prevents
Angptl4 oligomer formation, which leads to reduced
Angptl4 mediated inhibition of LPL activity [2].
Studies in large Western and Asian population cohorts
have proved an independent association between elevated
triglyceride levels and CVD risk [3, 4].
ANGPTL4 concentration has a positive correlation
with TG in patients with the metabolic syndrome [5]. A
cohort study described a significant negative correlation
between HDL-cholesterol and ANGPTL4 [5, 6]. There-
fore, ANGPTL4 could be associated with disorders of lipid
metabolism. This is also supported by human genetic data
including genome wide association studies [7].
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Population-based [8] studies and results in over 30,000
individuals from non-diabetic [7] have confirmed To
date, that the E40K loss-of-function variant is associated
with significantly lower triglyceride levels [7, 8]. In contrast,
the ANGPTL4 T266M cSNP, which is more prevalent than
E40K, has been shown to have a smaller effect on triglycer-
ide levels in non-diabetic populations [8].
The purpose of this study is to determine whether
the ANGPTL4 E40K and T266M polymorphisms are
associated with triglyceride levels in well characterized
patients with T2D, and with CVD risk factors, such as




A total of 220 type 2 diabetic patients, recruited through
the Fattouma Bourguiba hospital (Monastir, Tunisia),
were diagnosed by angiography. Subjects were defined
with cardiovascular disease (CAD) when presenting a
stenosis >50 % in at least one major coronary artery.
Subjects were defined without coronary artery disease
(No CAD) when presenting a stenosis <50 in at least
one major coronary artery. Hypertension was diagnosed
as a blood pressure of higher than 140/90 mmHg,
which was measured according to guidelines [9] and/or
the current use of anti-hypertensive drugs. Diabetic sub-
jects were defined by a fasting plasma glucose >7.0 mmol/
L, or by the use of anti-diabetic drugs [10]. Obese subjects
were defined by a BMI >30.0 Kg/m2. Data on age, sex,
smoking, and smoking history were collected from the
participants’ medical records or by direct interviews. Fast-
ing concentrations of TC, TG, LDL-C, and HDL-C were
measured using standard methods [11]. The metabolic
syndrome (MetS) was diagnosed when at least three of the
following criteria applied: triglycerides ≥150 mg/dl
(1.7 mmol/l), high density lipoprotein (HDL) choles-
terol <40 mg/dl (1.0 mmol/l) in men and <50 mg/dl
(1.3 mmol/l) in women, blood pressure ≥130/≥85 mm
Hg, or fasting glucose ≥100 mg/dl (5.6 mmol/l). This
study was approved by our hospital ethical committee
chaired by Pr Fekri Abroug, the reported investigations
have been carried out in accordance with the principles
of the Declaration of Helsinki as revised in 2008. All
participants were of Tunisian origin and gave their in-
formed consent for this study.
Biochemical analysis
Blood samples were taken for biochemical analysis fol-
lowing overnight fasting. Tch, triglyceride and HDL-c
concentrations were determined at accredited clinical
laboratories using routine clinical methods. LDL choles-
terol concentrations were calculated using the Friedewald
equation [12].
DNA analysis
Genomic DNA was prepared from white blood cells using
the salting-out method [13]. Genotypes for the variant
9p21.3 were determined by polymerase chain reaction
(PCR) amplification with fluorescent-labeled primers.
Genotyping
T266M polymorphism
This polymorphism was genotyped using the PCR-RFLP
(restriction fragment length polymorphism) method. Pri-
mer sequences are: forward primer: 5’- TGC CTC ATG
GAG TGG CCT CT-3’ and reverse primer : 5’-TGT CCT
CGC CAC CCA GGT-3’. Amplification was performed in
a total reaction volume of 20 μl each, containing 0.2 μM
deoxynucleotide triphosphates, 1× Taq buffer, 3 mM
MgCl2, 0.2 μM forward primer, 0.2 μM reverse primer
and 1.0 U Taq polymerase. Thermocycling consisted of an
initial denaturation step of 94 °C for 4 min followed by
35 cycles of 94 °C for 1mn s, 61 °C for 30 s, 72 °C for 40 s
and a final extension cycle of 72 °C for 7 min. The ampli-
fied products consisting of a 165 bp fragment was electro-
phoretically separated on 2 % agarose gels. The PCR
products were digested with restriction enzyme NlaIII and
incubated at 37 °C during one night. The digested products
consisting of: 156 + 9 bp for C allele and 94 + 62 + 9 bp for
T allele were analyzed on 3 % agarose gel.
E40K polymorphism
Allele specific primers for the ancestral (G) and derived
(A) alleles of rs1333049: G > A, were designed to select-
ively amplify the relevant target sequences [14]. The
sequence of the forward primer for the G allele was: 5′-
CTT TGC GTC CTG GGA CGA-3′ and for A allele the
sequence was: 5′-GCT TTG CGT CCT GGG ACA-3′.
The internal control primer sequence was: 5′-TGA TCC
GAT TCT TTC CAG C-3′. For all the forward primers
a common reverse primer was used, with the sequence:
5′-GGC TCT CCT GGC TTG GAA G-3′. Amplifica-
tion of ancestral and derived alleles was performed
separately in a total reaction volume of 20 μl each, con-
taining 0.2 μM deoxynucleotide triphosphates, 1× Taq
buffer, 3 mM MgCl2, 0.2 μM allele specific forward pri-
mer, 0.3 μM reverse primer, 0.1 μM internal control pri-
mer and 1.0 U Taq polymerase. Thermocycling consisted
of an initial denaturation step of 94 °C for 4 min followed
by 35 cycles of 94 °C for 1mn s, 61 °C for 30 s, 72 °C for
40 s and a final extension cycle of 72 °C for 7 min. The
amplified products consisting of a 222 and 223 bp frag-
ment for the allele specific primers (G and A respectively)
and 508 bp for the internal control were electrophoretic-
ally separated on 2 % agarose gels.
DNA bands were visualized by UV trans-illumination,
the image documented using the BioCap MW software
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(ver. 11.01, Vilber Lourmat, France) and the genotype
data were then calculated.
Statistical analyses
All statistical analysis was performed using version 11.0
of the Statistical Package for the Social Sciences: SPSS
(SPSS Inc., Chicago, Illinois, USA). Continuous variables
are presented as mean (95 % confidence intervals), and
categorical data are summarized as frequencies or per-
centages. Normal distribution of continuous variables
was evaluated with the Kolmolgorov-Smirnov test, and
differences among groups were analyzed by one-way
analysis of variance (ANOVA). For categorical variables,
differences between groups were evaluated by the chi-
square test. Odds ratios (ORs) of CAD for TT genotype
on rs1044250 (T266M variant) and GA genotype on
rs116843064 (E40K variant), and other risk factors, were
estimated by multivariate logistic regression analyses.
The significance of multiplicative interactions between
TT genotype (T266M variant) and GA genotype (E40K
variant) and covariates was determined by a Logistic
regression model. The relationship between genotype
and cardiovascular disease was evaluated with the
Mann–Whitney U-test. A 2-sided probability level of
≤0.05 was considered significant.
Results
Baseline characteristics of the study population
Table 1 shows clinical features of control group (with
No CAD) and CAD group. Compared to control group,
patients of the CAD group have an increased percentage
of obesity, MetS, hypertension, insulin and BMI, TG,
and LDL-C levels (all p < 0.05). No significant differences
in age, sex, smoking, fasting plasma glucose, HbA1c
and HDL-C levels were found between the groups (all
p > 0.05).
Association between rs116843064 polymorphism (E40K),
biochemical measurements and Clinical features
Biochemical measurements and clinical features with
respect to various genotypes are listed in Table 2.
There are no differences between the two genotypes in
the control group (all p > 0.005) except the TG level, it’s
lower in the heterozygote EK (p < 0.05). This genotype
has a larger effect in the CAD group, showing lower
BMI value, obesity and MetS percentages (all p < 0.05)
and especially lower TG levels (p < 0.001), compared to
EE homozygote. No differences were found in age, sex,
insulin percentages, fasting plasma glucose, HbA1C, TC,
HDL-C and LDL-C levels between the two genotypes of
rs116843064 polymorphism.
Association between rs1044250 polymorphism (T266M),
biochemical measurements and Clinical features
As shown on Table 3, among the three genotypes, there
are no differences in age, sex, hypertension, insulin per-
centages, fasting plasma glucose, HbA1C, TC, HDL-C
and LDL-C values between the two groups (all p > 0.05).
Compared to control group, there is a significant linear
decrease in the BMI value, obesity and MetS percentages
Table 1 Baseline characteristics of the study population
Control group (No CAD) Mean(95 % CI) CAD Mean(95 % CI) p
N 117 103 -
Age (years) 63,94(62,1–65,78) 66,13(64,21–68,07) 0,10
Sex (%men) 48,7 52,4 0,62
Smoking (%) 26,5 44,7 0,27
Fasting plasma glucose (mmol/L) 11,48(10,59–12,36) 12(10,96–13,05) 0,44
HbA1c (mmol/L) 10,48(9,72–11,23) 11,01(10,11–11,91) 0,37
BMI (kg/m2) 29,91(29,14–34,67) 36,23(30,41–45,06) 0,02
Obesity (%) 42,7 61,2 0,02
Metabolic syndrome (%) 26,5 52,4 <0,001
SBP (mm/Hg) 144,78(138,94–150,63) 145,68(139,99–151,37) 0,82
DBP(mm/Hg) 78(74,71–81,29) 87,60(83,21–92) 0,001
Hypertension (%) 52,1 75,7 <0,001
TC (mmol/L) 4,8(4,6–5) 4,87(4,63–5,11) 0,63
TG (mmol/L) 1,71(1,51–1,91) 2,90(2,62–3,17) <0,001
HDL-C (mmol/L) 1,33(1,24–1,41) 1,21(1,10–1,33) 0,10
LDL-C (mmol/L) 3,22(3–3,44) 4,40(4,08–4,71) <0,001
Insulin (%) 40,2 77,7 <0,001
Data presented is mean (95 % confidence intervals)
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among the three genotypes in the CAD group, these
values are significantly lower in MM genotype carriers.
Concerning the TG level, MM genotype has a significant
lowering effect in the control group (p = 0.04), but this
effect is larger in CAD group (p = 0.01).
Comparison between E40K and T266M effect on TG levels
Tables 2 and 3 show that the association of E40K and
T266M with triglyceride levels remained significant in
the two groups (p = 0.01 and p = 0.04 respectively), but
the association is more significant in the CAD group (p
< 0.001and p = 0.01 respectively), and as shown E40K
polymorphism has a larger effect in TG levels than
T266M polymorphism.
Multivariable analysis
A multiple logistic regression analysis was performed
with CAD as the dependent variable (Table 4). Analysis
showed that TT genotype of rs1044250 (T266M variant)
showed a protective effect on CVD risk in CAD group
patients (OR 1.92, 95 % CI 0.60–1.42, p =0.05) compared
with control Group patients (OR 1.17, 95 % CI 0.70–
1.66, p = 0.72). Likewise, GA genotype of rs116843064
(E40K variant): (OR 0.74, 95 % CI 0.54–1.65, p =0.01)
for the CAD group compared with control Group pa-
tients (OR 1.12, 95 % CI 0.68–1.74, p = 0.074). So, the
two genotypes of ANGPTL4 variants play a protective
role against CVD in Tunisian type 2 diabetic patients.
Discussion
The principal findings of this study are a confirmation of
an association of the E40K and T266M variants with
lower TG levels and predicts cardiovascular disease risk
in 220 Type 2 diabetic individuals. These results are
partly in agreement with the findings of Talmud et al.
[8] who examined 6 ANGPTL4 SNPs and reported that
E40K was associated with increased CVD risk and
T266M showed effects only under conditions of post-
prandial stress. But the functionality of these potential
“loss-of-function” variants needs validation.
Formation of Angptl4 oligomers by disulphide bonds
in the coiled-coil N-terminus [15] is required to inhibit
LPL activity. The E40K substitution destabilizes the pro-
tein after secretion, preventing the extracellular accumu-
lation of oligomers and abolishing the ability of the
Angptl4 protein to inhibit LPL activity [2].
Variant rs1044250 (T266M) is located in the C-
terminal region of ANGPTL4 and is conserved across
human, rat, and mouse species, supporting a functional
role [5, 16–18]. Thus, it may be assumed that rs1044250
may influence cardiovascular risk by decreasing
ANGPTL4 activity in endothelial cells increasing angio-
genesis and vascular permeability.
Smart-Haljko et al. [19] demonstrate for the first time
that the ANGPTL4 E40K and T266M variants are asso-
ciated with lower triglyceride levels in the setting of
T2D. In addition, their findings demonstrate that
ANGPTL4 genotype status does not alter triglyceride re-
sponse to a lifestyle intervention in the Look AHEAD
Table 2 Association between rs116843064 (E40K) polymorphism, biochemical measurements and clinical features
Control group Mean(95 % CI) CAD Mean(95 % CI)
EE (GG) EK (GA) p EE (GG) EK (GA) p
N 105 12 - 74 28 -
Age (years) 63,48(61,53–65,44) 67,92(61,97–73,87) 0,22 65,73(63,43–68,03) 67,1(63,24–70,98) 0,5
Sex (%men) 46,7 66,7 0,78 50 60,7 0,43
Fasting plasma glucose (mmol/L) 11,56(10,64–12,49) 10,74(7,20–14,28) 0,26 12,52(11,32–13,73) 10,48(8,34–12,61) 0,11
HbA1c (mmol/L) 10,55(9,76–11,34) 9,85(6,82–12,88) 0,22 11,49(10,42–12,56) 9,57(7,87–11,27) 0,08
BMI (kg/m2) 31,6(28,34–34,87) 29,71(28,93–30,49) 0,05 41,47(31,94–45) 31,16(30,15–32,17) 0,02
Obesity (%) 50 41,9 0,06 75,4 58,1 0,03
Metabolic syndrome (%) 26,7 25 0,12 47,3 67,9 <0,001
SBP (mm/Hg) 144,63(138,68–150,58) 146,17(119,19–173,14) 0,062 144,44(136,97–151,92) 148,14(140,8–155,48) 0,49
DBP(mm/Hg) 78,13(74,77–81,49) 76,83(61,87–91,8) 0,08 87,32(82,10–92,55) 87,89(78,99–96,8) 0,84
Hypertension (%) 51,4 58,3 0,64 71,6 85,7 0,12
TC (mmol/L) 4,79(4,58–5) 4,87(4,15–5,6) 0,27 4,73(4,44–5,03) 5,18(4,76–5,61) 0,06
TG (mmol/L) 1,72(1,51–1,94) 1,59(1,21–1,97) 0,01 1,9(1,59–2,2) 1,65(1,19–2,32) <0,001
HDL-C (mmol/L) 1,32(1,23–1,41) 1,43(1,19–1,67) 0,07 1,21(1,06–1,35) 1,23(1,03–1,44) 0,08
LDL-C (mmol/L) 3,2(2,97–3,44) 3,36(2,69–4,03) 0,06 4,36(3,99–4,73) 4,34(3,78–5,09) 0,07
Insulin (%) 41 33,3 0,33 75,7 82,1 0,44
Data presented is mean (95 % confidence intervals)
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Table 3 Association between rs116843064 (T266M) polymorphism, biochemical measurements and clinical features
No CAD CAD
TT TM MM p TT TM MM p
N 62 40 5 - 32 55 16 -
Age (years) 66,18(63,02–69,35) 63,54(62,11–65,92) 59,84(55–64,69) 0,06 67,14(64,11–70,18) 65,37(62,38–68,38) 65,62(60,12–71,13) 0,11
Sex (%men) 47,7 45,2 57,9 0,65 57,1 44,4 62,5 0,62
Fasting plasma glucose (mmol/L) 10,7(8,43–12,97) 11,56(10,13–12,99) 11,69(10,16–13,23) 0,74 11,31(8,91–13,71) 11,7(10–13,4) 12,53(10,86–14,2) 0,12
HbA1c (mmol/L) 10,18(8,08–12,27) 10,61(9,37–11,85) 11,01(9,68–12,34) 0,76 10,36(8,09–12,64) 10,73(9,4–12,07) 11,49(9,98–13) 0,76
BMI (kg/m2) 30,91(29,35–32,46) 29,62(28,59–30,64) 29,44(27,62–31,26) 0,27 42,32(40,83–43,80) 39,94(38,78–41,09) 32,03(30,68–33,37) 0,01
Obesity (%) 52,6 47,7 48,1 0,08 81,3 69 46,7 0,02
Metabolic syndrome (%) 26,2 27,3 26,8 0,21 62,5 51,9 41,94 0,01
SBP (mm/Hg) 149,33(137,59–161,08) 146,22(137,78–154–67) 137,05(121,5–152,6) 0,40 148,69(139,3–158,08) 143,62(134,51–152,74) 143,56(131,21–155;92) 0,16
DBP(mm/Hg) 82,59(76,56–88,64) 75,15(68,69–81,62) 75,13(69,34–80,94) 0,13 90,42(82,99–97,86) 83,97(77,06–90,9) 90,37(81,87–98,88) 0,17
Hypertension (%) 59,1 57,1 55,1 0,28 70 75 81,4 0,06
TC (mmol/L) 4,55(4,21–4,89) 4,87(4,58–5,16) 5,3(4,7–5,9) 0,44 4,71(4,18–5,24) 4,81(4,43–5,2) 4,98(4,59–5,38) 0,36
TG (mmol/L) 1,98(1,4–2,56) 1,75(1,41–2,09) 1,55(1,23–1,86) 0,04 2,53(2,47–3,19) 2,83(1,83–3,84) 3,23(2,53–3,45) 0,01
HDL-C (mmol/L) 1,3(1,06–1,54) 1,31(1,16–1,45) 1,41(1,28–1,55) 0,49 1,15(0,94–1,36) 1,19(0,99–1,40) 1,25(1,07–1,43) 0,68
LDL-C (mmol/L) 2,77(2,48–3,06) 3,31(2,94–3,68) 3,01(2,46–4,55) 0,31 3,25(3,07–1,43) 4,51(3,54–5,49) 4,74(4,24–5,24) 0,09
Insulin (%) 46,2 45,4 45,5 0,12 51,4 61,3 62,2 0,09
















study. The T266M TG effect is consistent with the
European Atherosclerosis Research Study II CHD off-
spring study which showed that MM homozygotes had
enhanced triglyceride clearance following an oral fat
tolerance test [8].
Our findings are confirmed by another study of
Muendlein et al. [20], they showed a positive association
of circulating ANGPTL4 levels as well as of ANGPTL4
SNPs with future cardiovascular risk in angiographically
characterized coronary patients.
Conclusion
ANGPTL4 variants are associated with, not only lower
fasting triglyceride levels, but also a decreased cardio-
vascular risk in T2D Tunisian patients.
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